Cardiovascular and cerebrovascular diseases
Conditions
Interventions
observation group :The observation group also received ticagrelor (Taiyi 90mg tablets, code: 01176201
Manufacturer: Shenzhen Xinyitai Pharmaceutical Co., Ltd.), administered twice daily at 90mg on non-dialysis days .
control group:The control group received no antiplatelet therapy, adhering to their original dialysis and baseline medication regimen.
Sponsors
The Second Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients must meet the 1999 Kidney Disease Outcome Quality Initiative (KDOQI) staging criteria for chronic kidney disease stage 5, undergoing maintenance haemodialysis at a frequency of three sessions per week or five sessions every two weeks, with adequate dialysis clearance. 2. Presence of cardiovascular risk factors: ? Diabetes mellitus ? Hypertension ? LDL cholesterol > 3.37 mmol/L ? Smoking ? Obesity (BMI = 28 kg/m²) ? Male > 55 years; female > 65 years ? Family history of cardiovascular disease ? Sleep apnoea syndrome 3. Patients and relatives provide informed consent; 4. Good treatment compliance; age 18–80 years. Must meet criteria1, 3, and 4 while satisfying any one criterion in 2.
Exclusion criteria
Exclusion criteria: 1. Presence of severe arrhythmia or cardiogenic shock; 2. Contraindications to study medications; 3. Concurrent malignant tumours, psychiatric disorders, haematological diseases, confirmed history of anticoagulant-induced thrombocytopenia; severe liver disease; 4. Recent major surgery, severe trauma, or serious infectious disease. 5. History of gastric ulcer, gastrointestinal haemorrhage, or cerebral haemorrhage within 1 year without follow-up examination within the last 3 months. 6. Patients with confirmed coronary heart disease or sequelae of cerebral infarction. 7. Patients requiring long-term anticoagulant therapy due to atrial fibrillation or thrombosis. 8. Participants who failed to undergo required examinations, had missing key indicators, or had participated in other clinical trials within the preceding three months. Any patient meeting any of the above criteria shall be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The composite endpoint of non-fatal acute coronary syndrome and acute cerebral infarction occurring during 12 months of regular follow-up in both groups.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome Name Incidence of bleeding events of different grades within 12 months of follow-up ;Cardio-cerebrovascular event-related mortality; | — |
Countries
Chain
Contacts
Public ContactKangquan Wu
The Second Affiliated Hospital of Guangdong Medical University
Outcome results
None listed